Concepedia

Dallas Bednarczyk

DB

20

Publications

1.1K

Citations

18

H-Index

1970

Active since

Affiliations

Novartis (United States)(Current)

University of Arizona

Optivia Biotechnology (United States)

Biogen (United States)

Pfizer (United States)

Dallas Bednarczyk is an author at Novartis (United States) specializing in biochemistry, medicine, and natural sciences.

ORCID

Top concepts

Publications per year

1970–2022

20

Publications

20

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text

Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

Irena Loryan, Andreas Reichel, Bo Feng et al. · Pharmaceutical Research · 2022 · 135 citations · Full text

Influence of Molecular Structure on Substrate Binding to the Human Organic Cation Transporter, hOCT1

Dallas Bednarczyk, Sean Ekins, James H. Wikel et al. · Molecular Pharmacology · 2003 · 113 citations · Full text

The activities of drug inactive ingredients on biological targets

Joshua Pottel, Duncan Armstrong, Ling Zou et al. · Science · 2020 · 86 citations · Full text

Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III

Dallas Bednarczyk, Carri Boiselle · Xenobiotica · 2015 · 81 citations

, , +14

Rows per page

1–5 of 20